MedTrace Logo

Assessments in Patients With Muscular Pathology and in Control Subjects : The ActiLiège Next Study

NCT05982119 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 300

Last updated 2025-05-20

No results posted yet for this study

Summary

The objective of the ActiLiège Next study is to collect longitudinal data from patients and control subjects using a wearable magneto-inertial device. By collecting natural history data in various neuromuscular disorders (Duchenne Muscular Dystrophy, Fascioscapulohumeral Muscular Dystrophy, Myotonic Dystrophy 1, Charcot-Marie-Tooth, Centronuclear Myopathy, Congenital Muscular Dystrophy), we aim to validate digital outcome measures to continuously assess motor function in real-life.

Conditions

  • Duchenne Muscular Dystrophy
  • Fascioscapulohumeral Muscular Dystrophy
  • Myotonic Dystrophy 1
  • Charcot-Marie-Tooth
  • Centronuclear Myopathy
  • Congenital Muscular Dystrophy

Interventions

DEVICE

ActiMyo/Syde

The two "watches" can be worn as wristwatch or placed near the ankle and on the wheelchair. * Patients with DMD or FKRP mutation will wear the ActiMyo°/Syde° during 3 months at baseline and then for one month every 3 months. * Patient with FSHD, DM1, CMT, CNM will wear the ActiMyo°/Syde° will wear the ActiMyo/Syde° during 3 months at baseline and then for one month every 6 months. * Control subjects \>4years will wear the ActiMyo°/Syde° during one month after inclusion and during one other month 11 months after inclusion. * Control subjects \<4years will wear the ActiMyo°/Syde° during one month after inclusion and during one other month every 6months after inclusion.

Sponsors & Collaborators

  • SYSNAV

    collaborator INDUSTRY

  • Centre Hospitalier Universitaire de Liege

    lead OTHER

Study Design

Allocation
NA
Purpose
BASIC_SCIENCE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
1 Year
Max Age
80 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-07-10
Primary Completion
2026-03-31
Completion
2026-03-31

Countries

  • Belgium
  • Czechia
  • Egypt
  • Hungary
  • Poland
  • Romania
  • Slovenia

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05982119 on ClinicalTrials.gov